ALK and non-small cell lung carcinoma: The three ALK inhibitors were selected due to their significant potential in clinical translation to treat ALK-driven NBL, as (1) all three ALK inhibitors have been approved by the FDA for treating NSCLC and (2) all have demonstrated in vitro and in vivo activity against ALK-positive NBL cells [12,37,38].